Upendra Marathi
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$13.8MFederal grants as PI15 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
15 awards · $13.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 30, 2024 | NIH | SBIR Phase II 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors | $999K | 7 Hills Pharma LLC |
| Jun 28, 2024 | NIH | SBIR Phase II Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | $998K | 7 Hills Pharma LLC |
| Mar 27, 2024 | NIH | SBIR Phase II 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination | $953K | 7 Hills Pharma LLC |
| Sep 19, 2023 | NIH | SBIR Phase II 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors | $999K | 7 Hills Pharma LLC |
| Jun 26, 2023 | NIH | SBIR Phase II Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | $998K | 7 Hills Pharma LLC |
| Apr 25, 2023 | NIH | SBIR Phase II 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination | $928K | 7 Hills Pharma LLC |
| Jul 13, 2022 | NIH | SBIR Phase II Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | $999K | 7 Hills Pharma LLC |
| Aug 12, 2021 | NIH | SBIR Phase II Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors | $1.0M | 7 Hills Pharma LLC |
| Apr 30, 2021 | NIH | SBIR Phase I Integrin Activation to Augment SARS-CoV-2 Vaccination | $298K | 7 Hills Pharma LLC |
| Sep 11, 2020 | NIH | SBIR Phase II Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors | $984K | 7 Hills Pharma LLC |
| Mar 29, 2019 | NIH | STTR Phase II Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | $1.0M | 7 Hills Pharma LLC |
| Apr 9, 2018 | NIH | STTR Phase II Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | $1000K | 7 Hills Pharma LLC |
| Apr 9, 2018 | NIH | STTR Phase II Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | $2.0M | 7 Hills Pharma LLC with UNIVERSITY OF TX MD ANDERSON CAN CTR |
| Jun 7, 2016 | NIH | STTR Phase I Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | $314K | 7 Hills Pharma LLC |
| Jun 6, 2016 | NIH | STTR Phase I Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer | $314K | 7 Hills Pharma LLC |
Peer ranks
Federal funding#23
Awards as PI#46
Patents#273
Companies
- 7 Hills Pharma LLCLinked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.